[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Liberia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":193},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,82,113,141,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645344","project-hope-hypertension-outreach-through-partnership-and-engagement-100645344",false,"NCT07681726","Project HOPE (Hypertension Outreach Through Partnership and Engagement)","HOPE","Patient Participant Inclusion Criteria:\n\n* Adults aged ≥25 years\n* Stage 2 hypertension defined as either:\n\n  * Systolic Blood Pressure (SBP) ≥160 mmHg at screening (Group A); OR\n  * SBP 140-159 mmHg at screening with either documented elevation on more than one visit or a known history of hypertension (e.g., prior clinician diagnosis or current use of antihypertensive medication) (Group B)\n\nPatient Participant Exclusion Criteria:\n\n* \\\u003C25 years of age\n* Hypertensive emergency with SBP ≥180 mmHg at screening (these patients will be referred to the nearest health center per local protocol; they may be re-screened for eligibility at a subsequent visit if SBP meets the inclusion criteria above)\n* Diagnosis of end-stage renal disease (ESRD)\n* Condition which interferes with outcome measurement (e.g., dialysis)\n* Serious medical condition which either limits life expectancy or requires active management (e.g., certain cancers)\n* Cognitive impairment or other condition preventing participation in the intervention\n* Active alcohol or substance use disorder (i.e., not sober\u002Fabstinent for ≥30 days), screened using the NIAAA Single Alcohol Screening Question\n* Pregnant or planning pregnancy in the next 24 months\n* Currently nursing a child\n* Current participation in another research study focused on reducing blood pressure\n* Current participation in a care management program related to health conditions (e.g., weight reduction, smoking cessation)\n* Planning to move out of the geographic area within 7 months\n* Unwillingness to provide informed consent\n\nCommunity Health Nurse (CHN) Participant Inclusion Criteria:\n\n* CHNs who were directly involved in delivering the nurse-led community-based hypertension intervention\n* Willing to provide oral informed consent for participation in pre\u002Fpost-training surveys and semi-structured interviews\n\nCommunity Health Nurse (CHN) Participant Exclusion Criteria:\n\n* CHNs who were not directly involved in the delivery of the intervention","ALL","25 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","The goal of this study is to learn if a nurse-led, task-shifting, community-based program can help lower blood pressure in adults aged 25 and older with uncontrolled high blood pressure (hypertension) in Monrovia, Liberia. The program is delivered through community-based mobile clinics by community health nurses (CHNs) trained in WHO-aligned hypertension care within the Ministry of Health's (MOH) Community Health hypertension management protocols.\n\nParticipants will:\n\n* Receive blood pressure treatment from trained community health nurses (CHNs) at community-based mobile clinics in their communities, including medication and lifestyle counseling.\n* Complete surveys at their first visit, at 4 to 6 weeks, and at 3 months about their experience, satisfaction, and medication use.\n* Attend follow-up visits at the mobile clinic based on their blood pressure levels.\n\nCommunity health nurses delivering the program will complete structured training and be invited to complete surveys before and after training, and to take part in interviews about their experience at the end of the study.\n\nThe study will take place over 7 months in five high-thoroughfare communities in Monrovia, Liberia, and aims to enroll 150 participants.",[24],"Hypertension (HTN)",[26,27,28,29,30,31,32,33],"Hypertension","Blood Pressure","Nurse-Led Intervention","Task Shifting","Community Health Nurses","Liberia","Mobile Clinic","Low-Resource Settings","NOT_YET_RECRUITING","2026-07-01",{"date":37,"type":38},"2026-07-06","ACTUAL",{"date":40,"type":20},"2026-09-01",{"date":42,"type":20},"2027-04-30",{"name":44,"class":45},"Johns Hopkins University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100630686","phase-3-combined-nutrition-and-parenting-study-100630686","NCT07490899","Combined Nutrition and Parenting Study","Impact of Combined Nutrition, Responsive Parenting, and Health Intervention on Childhood Development Study","BUNDLE","Inclusion Criteria:\n\n* Resides in selected community in Liberia\n* Household has a child aged 6-30 months at study enrollment\n* Child has a primary female caregiver and second (male or female) caregiver ≥ 18 years of age\n* Caregivers and child intend to continue residing in the study area for the follow-up duration\n* Both primary and second caregiver provide informed consent\n\nExclusion Criteria:\n\n* Children with known allergies to eggs or fish\n* Caregivers with cognitive and severe physical disabilities who are unable to implement intervention activities\n* Children with developmental disabilities",true,"6 Months","30 Months",{"count":59,"type":20},2240,"INTERVENTIONAL",[62],"PHASE3","This study aims to evaluate whether early childhood development is improved by a bundled set of interventions that promote responsive stimulation and improved nutrition by the provision of eggs and dried fish (nutrient-dense animal source foods), and whether, in combination, these stimulation and nutrition interventions are more effective than responsive stimulation or food provision alone.",[65],"Early Childhood Development (ECD)",[67,68,69,70,71],"cluster randomized trial","responsive caregiving","nutrition","early childhood development","animal source food","2026-03-18",{"date":74,"type":38},"2026-03-24",{"date":76,"type":20},"2027-02",{"date":78,"type":20},"2028-06",{"name":80,"class":45},"University of South Carolina",4,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":5},"100529110","health-systems-and-policy-contexts-of-medical-oxygen-100529110","NCT06169514","Health Systems and Policy Contexts of Medical Oxygen","Understanding the Health Systems and Policy Contexts of Medical Oxygen in Africa and Asia (MOXY-HSP)","MOXY-HSP","Key informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society.","18 Years",{"count":46,"type":20},"This is a mixed-methods program evaluation from a health systems and policy perspective, involving (i) stakeholder analysis, (ii) policy-implementation gap analysis, and (iii) comparative country case studies. This study aims to understand how national oxygen strategies achieve impact at national, and subnational level, across country contexts, at what cost.\n\nThe the investigators seek to:\n\n1. Involve policymakers, implementers (including private sector), and medical oxygen users in identifying challenges and understanding potential solutions to medical oxygen access;\n2. Generate new data on how medical oxygen systems work and can be improved from multiple perspectives;\n3. Draw lessons on medical oxygen that can directly inform national and global practice and policy.\n\nThis study will be conducted in 6 of the 9 countries participating in the Clinton Health Access Initiative (CHAI) led Medical Oxygen Implementation (MOXY) program (Uganda, Nigeria, Rwanda, Liberia, Lao PDR, Cambodia).\n\nKey informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society. This study will be completed over 4 years, with timelines varying between country study sites.",[94,95,96],"Hypoxemia","Morality","Pneumonia",[98,99,100,101,102],"Health system","Oxygen","Oxygen systems","Oxygen access","Pulse oximetry","RECRUITING","2026-02-04",{"date":106,"type":38},"2026-02-06",{"date":108,"type":38},"2024-07-31",{"date":110,"type":20},"2027-12",{"name":112,"class":45},"Murdoch Childrens Research Institute",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":60,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":81},"100532402","phase-2-isthanrs-0409s-integrate-lassa-fever-study-100532402","NCT06212336","ISTH\u002FANRS 0409s INTEGRATE Lassa Fever Study","Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African Countries","1. General\n\n   Inclusion criteria\n   * Clinical disease with signs and symptoms suggestive for LF\n   * Positive plasma LASV RT-PCR\n   * Participant requires hospitalization per the local guidelines\n   * Participant or their legally authorized representative is able and willing to sign the informed consent\n\n   Exclusion criteria\n   * Unwilling to provide informed consent\n   * Positive pregnancy test\n   * Unwilling to provide informed consent\n   * History of allergic reaction or other contra-indication to ribavirin according to the Reference safety document\n   * Received drug therapy for Lassa fever (excluding supportive care) prior to inclusion\n   * Has received a vaccine against LF\n2. Sub-protocols\n\n   2.1 Favipiravir high dose sub-protocol\n\n   Inclusion criteria • Age ≥ 18 years old\n\n   Exclusion criteria • Pregnancy (evidenced by positive urine pregnancy test in women of child-bearing potential)\n   * Treatment contraindicated with favipiravir according to the Reference safety document\n   * Pre-existing liver failure\n   * Severe symptomatic gout\u002Fhyperuricemia\n   * History of QT prolongation or arrhythmia or other cardiac disorders\n   * PR interval ≥ 200 ms\n   * Hypersensitivity to excipients\n   * Inability to take oral drug (e.g. encephalopathy, severe vomiting)\n\n   2.2. Favipiravir-Ribavirin sub-protocol\n\n   Inclusion criteria\n\n   • Age ≥ 18 years old\n\n   Exclusion criteria\n   * Pregnancy (evidenced by positive urine pregnancy test in women of child-bearing potential)\n   * Treatment contraindicated with favipiravir according to the Reference safety document\n   * Pre-existing liver failure\n   * Severe symptomatic gout\u002Fhyperuricemia\n   * History of QT prolongation or arrhythmia or other cardiac disorders\n   * PR interval ≥ 200 ms\n   * Hypersensitivity to excipients\n   * Inability to take oral drug (e.g. encephalopathy, severe vomiting)\n\n   2.3. Dexamethasone sub-protocol\n\n   Inclusion criteria • Age ≥ 12 years old\n\n   Exclusion criteria\n\n   • Pregnancy (evidenced by positive urine pregnancy test in women of child-bearing potential)\n\n   • Known intolerance and contra-indications to ribavirin or dexamethasone\n\n   • Patients who already received a corticosteroid within the preceding 7 days\n\n   2.4 ARN-75039 subprotocols\n\n   Exclusion criteria • History of severe gastrointestinal disease\n\n   • History of chronic generalized pruritus\n   * History of severe chronic liver disease\n   * History of severe cardiac disorder",{"count":121,"type":20},1755,[123,62],"PHASE2","Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%. Transmission to humans occurs mainly via direct or indirect exposure to excreta from the rodent reservoir, mainly made up of Mastomys natalensis . Less frequently, LASV may also be transmitted from human to human and cause nosocomial outbreaks. Ribavirin is the only treatment available with worrying toxicity, questionable efficacy and low access because of its high cost. Consequently, there is an urgent need for new drugs to treat LF patients. The Research and Development (R\\&D) Blueprint of the World Health Organization (WHO) has included LF in the list of priority diseases for urgent research and development.\n\nThe INTEGRATE consortium is an unprecedented international collaboration on Lassa fever of 15 partners from 10 countries across West Africa, Europe and North America and across several disciplines (epidemiological researchers, social scientists, medical health facility professionals, humanitarian actors, etc.).",[126],"Lassa Fever",[128,129,130,131,132],"emerging infectious diseases","viral hemorrhagic fever","AFRICA","adult","adolescent","2026-02-02",{"date":104,"type":38},{"date":136,"type":38},"2025-05-02",{"date":138,"type":20},"2027-06",{"name":140,"class":45},"Irrua Specialist Teaching Hospital",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":60,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":81},"100580769","phase-3-ebola-post-exposure-prophylaxis-100580769","NCT06841614","EBOla Post-Exposure Prophylaxis","Evaluation of the Efficacy of a Post-exposure Prophylaxis (PEP) Strategy in Contacts at High Risk of Developing Ebola Virus Disease (EVD)","EBO-PEP","Inclusion criteria\n\n* Last high-risk contact within the last 5 days\n* No sign or symptoms of EVD\n* Signed and dated informed consent from participants over the age of majority to participate in the trial or from a representative of parental authority for minor participants.\n\nNon-inclusion criteria\n\n* History of vaccination with Ervebo or any other EVD vaccine within the last 5 years (self-reported by the participant)\n* History of confirmed EVD within the last 5 years (self-reported by the participant)\n* Hypersensitivity to any of the experimental medical products (IMP) or their excipients (self-reported by the participant)\n* Participation in another therapeutic or vaccine trial for EVD\n* Any other reason that, at the investigator's discretion, could compromise the participant's safety and cooperation in the trial.",{"count":150,"type":20},160,[62],"EBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms.\n\nThe trial will be open during EVD epidemics and will recruit asymptomatic participants at high risk of developing EVD.\n\nParticipants will be randomized (1:1) into one of two trial arms:\n\n* Arm 1 (ERV): Ervebo D0 (72 million PFU IM)\n* Arm 2 (ERV+IMZ): Ervebo D0 (72 million PFU IM) + Inmazeb IV (150 mg\u002Fkg) D0 + Ervebo D56 (revaccination)\n\nDefinition of high-risk:\n\nDirect contact with a person with EBOV PCR-confirmed EVD with diarrhea, vomiting or external bleeding (\"wet symptoms\"), or with their body fluids; Direct contact with the dead body of a person with confirmed or probable EVD; Needlestick with a syringe contaminated by the blood of a person with confirmed or probable EVD; Or a child born to or breastfed by an individual with EVD\n\nTrial follow-up All participants are monitored daily for a minimum of 21 days.\n\nSome visits are conducted in person at the investigation site, also called the Post-Exposure Prophylaxis (PEP) center:\n\n* at Day 5, Day 10, and Day 21 for the ERV arm,\n* at Day 5, Day 10, Day 21, and Day 56 for the ERV+IMZ arm. Other visits are conducted at home or by phone, in collaboration with the Ministry of Health's surveillance team.\n\nParticipants in the ERV+IMZ arm have an in-person visit at Day 56 to be revaccinated with the Ervebo vaccine to compensate for potential inhibition of the vaccine response when Ervebo is administered simultaneously with Inmazeb.\n\nParticipants in the ERV arm have a phone visit at Day 56. For all participants, a phone visit is scheduled at Day 60. It corresponds to the last visit for all trial participants.\n\nFollow-up in Case of Hospitalisation In case of clinical signs suggestive of EVD, participants enter the suspected case management pathway at the Ebola Treatment Center (ETC).\n\nIf EVD is confirmed by EBOV PCR, participants are allowed at the ETC, and their study samples are discontinued. They continue to be followed by the research team, and daily data are collected throughout their stay at the ETC until they are discharged alive or deceased. The day of discharge from the ETC marks the end of follow-up in the study for these participants.\n\nOf note, participants in the ERV+IMZ arm who have confirmed EVD are not revaccinated at day 56.\n\nOf note, participants in the ERV+IMZ arm who have confirmed EVD are not revaccinated at day 56.\n\nIf EVD is not confirmed, participants continue to be followed up by the PEP center according to the protocol.",[154],"Ebola Virus Disease",[154,156,157,158],"EBOV","High-Risk contact","Post-Exposure Prophylaxis","2026-01-21",{"date":161,"type":38},"2026-01-22",{"date":163,"type":20},"2026-09",{"date":165,"type":20},"2028-08-01",{"name":167,"class":168},"ANRS, Emerging Infectious Diseases","OTHER_GOV",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":55,"sex":16,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":60,"phases":180,"briefSummary":174,"conditions":181,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":192},"100506003","phase-2-a-lassa-fever-vaccine-trial-in-adults-and-children-residing-in-west-africa-100506003","NCT05868733","A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa","A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa","Inclusion Criteria:\n\n* Adults, adolescents, and children in good general health as assessed by medical history and physical examination (group-specific criteria apply).\n* At least 18 months old on the day of screening and not more than 70 years old on the day of vaccination (group-specific criteria apply).\n* Participant or parent\u002Fguardian willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.\n* In the opinion of the Principal Investigator (PI) or designee and based on Assessment of Informed Consent Understanding (AOU), participant or parent\u002Fguardian has understood the information provided and potential impact and\u002For risks linked to administration and participation in the trial; written informed consent will be obtained before any study-related procedures are performed. Children old enough to understand the procedures will be asked to assent, in addition to parent\u002Fguardian consent, in accordance with local requirements.\n* Willing to undergo HIV testing, risk reduction counselling, and receive HIV test results (group-specific timepoints apply).\n* All participants of child-bearing potential engaging in sexual activity that could lead to pregnancy must commit to use an effective hormonal contraception or intrauterine device beginning 2 weeks prior and extending for 4 months following receipt of vaccine\u002Fplacebo. Study sites will choose which methods are most appropriate for their population and this will be specified in the Informed Consent Document (ICD).\n* All sexually active participants must consistently use male or female condoms with all sexual partners for 4 months following IP administration.\n* All participants who are not engaging in sexual activity that could lead to pregnancy at screening must agree to utilize an effective method of contraception if they begin engaging in sexual activity that could lead to pregnancy, as outlined above.\n* All participants of childbearing potential must be willing to undergo a pregnancy test at time points indicated in the SOA.\n* Willing to forgo donation of blood or any other tissues for transfusion or transplantation, from screening onward throughout the course of the study.\n\nAdditional Inclusion Criteria For HIV-Infected Participants\n\n* Adults who are HIV-infected must meet the following additional inclusion criteria:\n* Participant must be aged at least 18 years old on the day of screening and not more than 50 years old on the day of vaccination.\n* Participant must have documented HIV-1 or HIV-2 infection for at least 6 months prior to screening.\n* Participant must be on a stable (at least 6 months) regimen of Highly Active Antiretroviral Therapy (HAART), as defined as potent anti-HIV treatment including a combination of antiretroviral agents (pre- or post-exposure prophylaxis does not count as HAART).\n* Participant entering the study should have a screening viral load \\\u003C50 copies\u002Fml.\n* Participant must be willing to continue their HAART and HIV care follow up throughout the study as directed by their regular caregiver and be willing to give access to records of their ongoing care.\n* Participant must be in an otherwise reasonably good medical condition (absence of acquired immunodeficiency syndrome \\[AIDS\\]-defining illnesses or clinically significant disease), diagnosed based on physical examination, medical history, and the investigator's clinical judgment.\n\nAdditional Inclusion Criteria for Pediatric Participants\n\n* Each potential pediatric study participant must meet all of the following additional criteria to be enrolled in the study:\n* Parent(s)\u002Flegal guardian must have signed an ICD indicating that they understand the purpose and procedures required for the study, are willing\u002Fable to adhere to the study requirements and are willing for their child to participate in the study. Assent must be obtained from adolescents and children in accordance with local regulations and practice. Parent(s)\u002Flegal guardian must pass the AOU.\n* Participant's age on the day of vaccination is within one of the 3 age strata in the study: 12-17 years, 6-11 years, or 18 months -5 years.\n* Participant must be healthy in the investigator's clinical judgment (and the parent(s)\u002Flegal guardian's judgment) based on medical history, physical examination and vital signs performed at screening.\n* A female adolescent who is of childbearing potential must comply with requirements for contraception.\n* Adolescents who are sexually active must comply with requirement for use of condoms for 4 months after vaccination.\n* Participant has received all routine immunizations appropriate for their age as reported by the parent(s)\u002Flegal guardian, according to local routine vaccination schedules. Participants are allowed to catch up on routine immunizations if needed or as part of national immunization campaigns. However, Exclusion Criteria #9 will apply.\n\nExclusion Criteria:\n\n* Confirmed HIV-1 or HIV-2 infection (except as outlined for Group 2)\n* Any clinically relevant abnormality on history or examination including history of immunodeficiency (except for Group 2) or autoimmune disease; use of corticosteroids, immunosuppressive, anticancer, or other medications considered significant by the Investigator within the previous 6 months. The following exceptions are permitted and will not preclude study participation: use of corticosteroid nasal spray for rhinitis, topical corticosteroids for an acute uncomplicated dermatitis; or a short course (duration of 10 days or less, or a single injection) of corticosteroid for a non-chronic condition (based on Investigator clinical judgment) at least 2 weeks prior to enrollment in this study.\n* Any clinically significant chronic medical condition that, in the opinion of the Investigator, makes the participant unsuitable for participation in the study (except for HIV in Group 2). Note: Participants aged \\>50years with the following chronic but controlled conditions may be enrolled:\n* Hypertension with systolic ≤150 mmHg and\u002For diastolic ≤90 mmHg; (regardless of treatment status)\n* Diabetes mellitus with a HbA1C \\\u003C10% and \u002For with type 2 diabetes mellitus on stable medication for at least 2 months prior to enrollment.\n* Pregnant or lactating.\n* Bleeding disorder that was diagnosed by a physician (eg, factor deficiency, coagulopathy, or platelet disorder that requires special precautions). Note: A participant who states that he or she has easy bruising or bleeding but does not have a formal diagnosis and has intramuscular (IM) injections and blood draws without any adverse experience is eligible.\n* Infectious disease: chronic active hepatitis B infection (HBsAg-positive), current hepatitis C infection, prior clinical diagnosis of Lassa Fever disease (LF) or Ebola virus disease (EVD) by medical history, active syphilis (positive screening and confirmatory tests unless adequately treated), positive viral detection test for SARS-CoV-2. Note: COVID-19 screening is not applicable for Group 5.\n* History of splenectomy or functional asplenia.\n* Any of the following abnormal laboratory parameters listed below:\n* Hematology\n* Absolute Neutrophil Count (ANC): ≤1,000 cells\u002Fmm3 or ≤ 1.0 × 109 cells\u002FL\n* Absolute Lymphocyte Count (ALC): ≤650 cells\u002Fmm3 or ≤ 0.65 × 109 cells\u002FL\n* Hemoglobin: \\\u003C9.5 g\u002Fdl in females; \\\u003C11.0 g\u002Fdl in males; \\\u003C10 g\u002Fdl in children \\\u003C11 years of age\n* Platelets \\\u003C100,000 cells\u002Fmm3\n* Chemistry\n* Creatinine \\>1.1 x upper limit of normal (ULN) (Note: For participants aged \\>50 years clinically insignificant renal insufficiency defined as creatinine ≤1.3 x ULN is allowed)\n* Alanine transaminase (ALT) \\>1.25 x ULN\n* Aspartate transaminase (AST) \\>1.25 x ULN\n* Urinalysis (not applicable for group 5)\n* Clinically significant abnormal dipstick confirmed by repeat dipstick on new specimen or by microscopy\n* Protein = 1+ or more\n* Blood = 2+ or more (not due to menses) (Urinalysis may be collected within the following 2 weeks if menses interfere)\n* Receipt of any vaccine within the previous 28 days or planned receipt within 28 days after vaccination with IP. Participation may be delayed until this criterion can be fulfilled. Note: prior receipt of VSV-vectored vaccines such as VSV-ZEBOV will be documented but is not an exclusion criterion.\n* Prior receipt of another investigational Lassa vaccine candidate. Note: receipt of placebo in a previous LF vaccine trial will not exclude a participant from participation if documentation is available and the Medical Monitor gives approval.\n* Receipt of blood transfusion or blood-derived products within the previous 3 months.\n* Participation in another clinical trial or observational study currently, within the previous 3 months, or expected participation during this study, unless Medical Monitor approves.\n* History of severe local or systemic reactogenicity to any vaccine (eg, anaphylaxis, respiratory difficulties, angioedema, injection site necrosis, or ulceration).\n* Psychiatric condition or substance abuse that compromises safety of the participant and precludes compliance with the protocol. Specifically excluded are persons with psychoses in the last 3 years prior to screening, ongoing risk for suicide, or history of suicide attempt or gesture in the last 3 years prior to screening.\n* Seizure disorder: A participant who has had a seizure in the last 3 years prior to screening or has been on any medication to control or prevent seizures for the last 3 years is excluded. Group 5: History of febrile seizures is an exclusion criterion.\n* A history of malignancy in the past 5 years (prior to screening) or ongoing malignancy (a history of a completely excised malignancy that is considered cured is not an exclusion).\n* Active, serious infections requiring parenteral antibiotic, antiviral, antiparasitic or antifungal therapy within 30 days prior to enrollment (except HAART treatment in Group 2). Asymptomatic malaria infection at study entry will be assessed retrospectively and will not be a basis for exclusion.\n* Group specific weight for height restrictions as indicated below:\n* Groups 1 and 2: Obesity as defined by Body mass index (BMI) ≥35.\n* Group 3: Obesity as defined by weight for height 2 standard deviation (SD) from median according to WHO growth charts or underweight as defined by weight for height or weight for length ≤-2 SD from median according to WHO growth charts\n* Groups 4 and 5: Underweight as defined by weight for height or weight for length ≤ 2 SD from median according to WHO growth charts (see APPENDIX C) and\u002For weighing \\\u003C10kg.\n* Group specific hearing thresholds or otoacoustic emission (OAE) results at 0.5-4KHz as indicated below:\n* Moderate or greater hearing impairment defined as 35dB in any frequency in either ear as revealed via the audiometry exam for Groups 1 and 2.\n* Mild or greater hearing impairment defined as ≥20dB in any frequency in either ear as revealed via the audiometry exam for adolescents and children aged \\>7years.\n\nFor children 7 years of age and younger (or unable to follow pure tone audiometry procedure) \"refer\" test results as determined by OAE.\n\n* Otorrhea within the past 90 days, sudden or rapid hearing loss within the past 90 days, acute or chronic dizziness, otalgia (external ear otalgia is not an exclusion)\n* Clinically relevant abnormal otoscopy, that in the opinion of the investigator, may interfere with hearing. (Participants with conditions that can be treated prior to enrolment such as cerumen obstruction are not excluded)\n* History of acute or chronic or severe neurologic condition (eg, diagnosis of Guillain-Barré syndrome, epilepsy, Bell's palsy, meningitis, or disease with any focal neurologic deficits).\n* Current of past significant risk factors for hearing loss (eg, occupational exposure to loud noise or medical illness) that, in the opinion of the investigator, may interfere with the detection of changes in hearing during the study.\n* History of any condition associated with sensorineural hearing loss that, in the opinion of the investigator, may cause changes in hearing during the study (eg, occupational exposure to loud noise or medical illness).\n* If, in the opinion of the PI, it is not in the best interest of the participant to participate in the study.","18 Months","70 Years",{"count":179,"type":20},612,[123],[126],"2025-05-07",{"date":184,"type":38},"2025-05-11",{"date":186,"type":38},"2024-03-06",{"date":188,"type":20},"2027-04",{"name":190,"class":191},"International AIDS Vaccine Initiative","NETWORK",3,""]